Genentech Expresses "Concern" About FDA Drug Approvals In McClellan’s Absence
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug approval timelines and FDA’s "spirit of urgency" could be impacted by the commissioner’s departure for CMS.
You may also be interested in...
BIO Is “Cautiously Optimistic” About Post-McClellan FDA
Senior agency officials appear committed to outgoing commissioner’s goals, BIO policy chief Werner says.
BIO Is “Cautiously Optimistic” About Post-McClellan FDA
Senior agency officials appear committed to outgoing commissioner’s goals, BIO policy chief Werner says.
Crawford Will Lead A Reorganized FDA As McClellan Leaves For CMS
FDA is implementing a three-deputy commissioner structure on an acting basis to ensure a smooth transition. Selection of a permanent commissioner is unlikely before the November elections.